Chemo-Free Regimen May Be Effective Option for EGFR-Mutant Lung Cancer

(MedPage Today) -- A three-drug combination may be effective for patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) who progressed on a third-generation EGFR tyrosine kinase inhibitor (TKI), according to a single-arm phase II...